Loss of anti-spike antibodies following mRNA vaccination for COVID-19 among patients with multiple myeloma.
Cancer Rep (Hoboken)
; 6(5): e1803, 2023 05.
Article
in En
| MEDLINE
| ID: mdl-36891732
ABSTRACT
BACKGROUND:
Multiple myeloma (MM) patients have variable responses to mRNA vaccination to COVID-19. Little is known regarding their vaccine-induced antibody levels over time.METHODS:
We monitored spike IgG antibody levels over 24 weeks among a subset of 18 MM patients who showed a full response after two mRNA vaccinations.RESULTS:
MM patients had a more rapid decline in antibody levels as compared to eight healthy controls, with power law half-lives of 72 days (vs. 107 days) and exponential half-lives of 37 days (vs. 51 days). The patients with longer SARS-CoV-2 antibody half-lives were more likely to have undetectable monoclonal protein than those with shorter half-lives, suggesting better disease control may correlate with longer duration of vaccine-induced antibodies. Regardless, by 16 weeks post-second dose of mRNA vaccination, the majority of patients had antibody levels below 250 binding arbitrary units per milliliter, which would be unlikely to contribute to preventing COVID-19.CONCLUSIONS:
Thus, even MM patients who respond adequately to vaccination are likely to require more frequent booster doses than the general population.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
COVID-19
/
Multiple Myeloma
Limits:
Humans
Language:
En
Journal:
Cancer Rep (Hoboken)
Year:
2023
Document type:
Article
Affiliation country:
United States